Since the discovery of ALK-rearranged lung cancers in 2007 [11], several ALK inhibitors have been developed and approved for clinical use, such as the first-generation ALK inhibitor Crizotinib (Xalkori), or the second-generation inhibitor Alectinib (Alecensa) [12]. Here, ALK is linked to lung carcinoma.